Close

BioBlast Pharma (ORPN) Announces Results from PK Study of IV Trehalose; Linearity Noted

Go back to BioBlast Pharma (ORPN) Announces Results from PK Study of IV Trehalose; Linearity Noted

Bioblast Announces Results of Trehalose Clinical Study

October 24, 2016 6:00 AM EDT

Pharmacokinetic Study in Healthy Volunteers Demonstrated Trehalose to be Safe and Well Tolerated at Twice the Dose Levels Used in Prior Clinical Studies

Results Support Weight-Based Dosing Paradigm in Future Studies

TEL AVIV, Israel, Oct. 24, 2016 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced results of a double-blind, placebo-controlled pharmacokinetic (PK) study of intravenous (IV) trehalose 90mg/mL in healthy volunteers.

The primary objective of the study was to establish safety and tolerability of escalating doses of... More